Plavsic Mark 4

What Happened

• Mark Plavsic, Chief Technology Officer of Aura Biosciences (AURA), received two awards on March 2, 2026 totaling 175,000 shares: 62,339 shares via RSUs and 112,661 shares as a derivative award. Both were reported with an acquisition price of $0.00 (awards/grants), i.e., compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-03-02; Form 4 filed: 2026-03-03.
• Items granted: 62,339 RSUs (acquisition code A) and 112,661 derivative shares/options (acquisition code A); both at $0.00 per share (total reported value $0).
• Shares owned after the transaction: not specified in the filing.
• Footnotes from the filing:
  • F1: The 62,339 RSUs each convert to one share and vest in four substantially equal annual installments beginning Jan 15, 2027, subject to continued service.
  • F2: The derivative award vests 25% on Feb 1, 2027, with the remainder vesting pro rata over 36 monthly installments, subject to continued service.
• Filing timeliness: Form 4 was filed the day after the reported grants (not indicated as late in the filing).

Context

• These grants are typical equity compensation intended to retain and incentivize executives. RSUs convert to shares as they vest; the derivative award appears to be an option-style grant subject to vesting and is not immediately exercisable.
• Because these were awards (not purchases or sales), they do not reflect an immediate personal cash investment or liquidation by the insider.